China biotech InxMed bags $19M Series A+ to develop PhI FAK inhibitor

Nicole DeFeudis

Editor

Nearly a year after Nanjing, China-based InxMed bagged its first-ever IND approval, the company has raked in ¥130 million (about $19 million) in a Series …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

China biotech InxMed bags $19M Series A+ to develop PhI FAK inhibitor

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

BridgeBio oncology spinout to go public via combination with SPAC from Cormorant and Bihua Chen

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

Pfizer vet William Pao’s next venture; Sanofi’s computational science exec leaves

Lilly joins molecular glue field with Magnet deal worth up to $1.25B

How AI can address ongoing challenges in the life sciences industry

Chi­na biotech In­xMed bags $19M Se­ries A+ to de­vel­op PhI FAK in­hibitor

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

China biotech InxMed bags $19M Series A+ to develop PhI FAK inhibitor